Serotonin syndrome and neuroleptic malignant syndrome are the two psychiatric medication emergencies. Both can be fatal; both require rapid recognition and intervention; both share enough features that distinguishing them at the bedside is one of the more important clinical skills in psychopharmacology.
- Class
- Psychiatric medication emergencies
- Mechanism
- Serotonin syndrome: excessive serotonergic activity from drug combination. NMS: idiosyncratic D2 blockade reaction.
- FDA indications
- Recognition and management of life-threatening drug reactions
- Key adverse effects
- Both feature autonomic instability, hyperthermia, altered mental status. Distinguishing features critical for treatment.
Serotonin syndrome: rapid onset (hours), hyperreflexia, clonus (especially lower extremity), tremor, GI symptoms (diarrhea, hyperactive bowel sounds), recent serotonergic drug exposure or combination. Management: discontinue serotonergic agents, supportive care, cyproheptadine, benzodiazepines for agitation. NMS: slow onset (days), lead-pipe rigidity, hyporeflexia, autonomic instability, elevated CK, antipsychotic exposure. Management: discontinue antipsychotic, supportive care, dantrolene or bromocriptine for severe cases.
Shared features: autonomic instability (BP swings, tachycardia, diaphoresis), hyperthermia, altered mental status. These commonalities are what make the syndromes confusable.
Distinguishing features: Onset speed — NMS develops over days (typically 1-3 days after antipsychotic initiation or dose change); serotonin syndrome develops over hours after the offending combination. Neuromuscular — NMS produces lead-pipe rigidity with hyporeflexia; serotonin syndrome produces hyperreflexia with clonus, especially in lower extremities. GI symptoms — prominent in serotonin syndrome (diarrhea, hyperactive bowel sounds); usually absent or minimal in NMS. Drug history — NMS follows antipsychotic exposure; serotonin syndrome follows a serotonergic drug combination.
Serotonin syndrome and neuroleptic malignant syndrome are the two psychiatric pharmacologic emergencies — distinguished by mechanism, onset, and a few discriminating clinical signs.
Mechanism note: Serotonin syndrome (serotonergic excess; fast onset; clonus/hyperreflexia) and NMS (dopamine blockade; slow onset; lead-pipe rigidity, high CK) are distinct emergencies — the neuromuscular exam discriminates them.
Serotonin syndrome triggers to know: SSRI plus MAOI (the most dangerous; never combine). SSRI plus tramadol. SSRI plus dextromethorphan. SSRI plus linezolid (a weak MAOI antibiotic). SSRI plus St. John's Wort. MAOI plus meperidine. The classic Sternbach criteria or the more recent Hunter criteria can formalize diagnosis, but bedside recognition of hyperreflexia and clonus in a patient on multiple serotonergic agents is usually clear enough.
Management: Both — discontinue offending agents, supportive care (cooling, hydration, electrolyte correction), ICU-level monitoring if severe. Serotonin syndrome — cyproheptadine 12 mg loading then 2 mg every 2 hours (serotonin antagonist), benzodiazepines for agitation. NMS — dantrolene for muscle rigidity in severe cases, bromocriptine (D2 agonist) sometimes used.
Future prescribing after either syndrome requires care. After NMS, future antipsychotic exposure is high-risk; consider clozapine or quetiapine (lower NMS risk), slow titration, careful monitoring. After serotonin syndrome, document the offending combination and educate the patient — they need to alert every future prescriber to the history.
Recognition saves lives. Hyperreflexia plus clonus plus serotonergic drug history = serotonin syndrome. Lead-pipe rigidity plus antipsychotic exposure = NMS. The distinction shapes treatment.